Oncology

Cancer cell
#Biomarkers #Breast cancer #Cancer research #Genetics / genomics #Oncology #Personalised medicine #The Institute of Cancer Research

Genetic biomarkers could personalise therapy for TNBC

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours… Read More

#Cancer Research #News #Trending News

Prostate cancer cells
#FDA #Gene mutation #Janssen #Oncology #Phase III trial #Prostate cancer

FDA approves dual action tablet for BRCA-positive prostate cancer

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. It is the first dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone,… Read More

#News #Regulatory

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

New DDW Highlights podcast now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news headlines this week reflect the level of interest in cell & gene… Read More

#News

FDA
#Bispecific Antibodies #FDA #Janssen #Myeloma #Oncology

Janssen myeloma drug approved in US via a restricted programme

The FDA has granted accelerated approval to Janssen’s talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma. It has been approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Read More

#News #Regulatory

Tumour microenvironment
#Cancer research #Cancer Research UK #Immunotherapy #Oncology #Phase I trial #Solid tumours #Sosei Heptares

Immunotherapy for solid tumours progresses to human trials

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating… Read More

#Cancer Research #News

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

This week in drug discovery (7-11 August)  

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful… Read More

#News

Warfarin
#Cancer research #Columbia University #Drug repurposing #Oncology

Warfarin could be repurposed as a potent cancer drug

A new study has shown that blood thinner warfarin could also treat cancer, as it stops tumours from interfering with a self-destruct mechanism that cells initiate when they detect mutations or other abnormalities (ferroptosis). The research by Columbia University researchers was conducted in human cells and… Read More

#Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #Genetics / genomics #Interview #Oncology #Sitting Down With

Sitting down with… Neil Dhawan

Listen to this article on the DDW Podcast: Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#Aleta Biotherapeutics #Biologics #Cancer research #Cancer Research UK #CAR-T #MHRA #Oncology

Biologic CAR-T cell engager approved for UK clinical trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer… Read More

#Cancer Research #News #Regulatory

#Astex Pharmaceuticals #Cancer research #Collaboration #Merck #Oncology

Astex and MSD expand cancer drug discovery collaboration

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. Under the terms of the agreement, Astex will apply its fragment-based drug discovery platform to… Read More

#Business & Investment #News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

DDW Highlights: 7 August 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The pace of innovation in cancer drug discovery showed no signs of slowing… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (31 July – 4 August)  

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a… Read More

#News

Endometrial cancer
#Cancer treatment #FDA #GSK #Oncology #Regulatory

FDA approves Jemperli plus chemo in endometrial cancer

GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with… Read More

#News #Regulatory

Breast cancer cell
#Cancer research #Gene mutation #Oncology #PARP inhibitors #The Institute of Cancer Research

PARP inhibitor use could be extended to more cancer patients

New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene. If further research supports these findings, there is the potential that existing PARP inhibitor… Read More

#Cancer Research #Editor's Choice #News

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News